Abstract
BackgroundCongenital cytomegalovirus (cCMV) infection can cause severe neurological damage, growth retardation, hearing loss, and microcephaly in infants. We aimed at assessing healthcare costs of infants with recorded cCMV diagnosis in an administrative claims database in the first 2 years of life.MethodsWe conducted a retrospective, controlled cohort study using German claims data from the Institute for Applied Health Research Berlin (InGef) database. Incremental healthcare costs during the first and second year of life were assessed by matching (1:60) infants with cCMV diagnoses †90 days after birth (cCMV90 cohort) to infants without cCMV diagnosis (ârepresentativeâ controls) and infants with cCMV diagnoses †21 days after birth plus specific symptoms (cCMV21-S) to infants without cCMV and any ICD-10-GM records (besides Z00-Z99) until 4th preventive health check-up (âhealthyâ controls). Due to missing data, mean imputation was applied for aids and remedies costs.ResultsWe identified 54 and 24 infants born 2014â2018 for the cCMV90 and cCMV21-S cohorts, respectively. During the first year, mean (median) healthcare costs were significantly higher in cCMV90 cases vs. ârepresentativeâ controls (âŹ22,737 (âŹ9759) vs. âŹ3091 (âŹ863), p < 0.001), with 87.2% inpatient costs. Healthcare costs for cCMV21-S cases compared to âhealthyâ controls were âŹ34,498 (âŹ20,924) vs. âŹ680 (âŹ569), p < 0.001. Differences decreased for both comparisons in the second year but remained statistically significant.ConclusionscCMV comprises a considerable economic burden for the German healthcare system (âŹ19,646 to âŹ33,818 higher mean costs for infants with recorded cCMV diagnosis in the first year of life). Attempts should be made to reduce this burden.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have